Abstract | OBJECTIVES: This study aimed to explore the effects of metformin on osteogenic differentiation of alveolar bone marrow mesenchymal stem cells (BMSCs) from type-2 diabetes mellitus (T2DM) patients (DM-BMSCs) and implant osseointegration in rats, screen the optimal concentration, and investigate whether metformin could protect against the adverse impact of T2DM on BMSC osteogenic capacity. SUBJECTS AND METHODS: Different concentrations of metformin were administered to human-derived BMSCs and Wistar rats receiving implants. ALP detection, alizarin red staining, real-time RT-PCR and Western blotting were performed to detect osteogenesis and investigate the mechanism. Toluidine blue staining was performed to analyse bone-implant contact in rats. RESULTS:
Metformin increased implant osseointegration in a rat model and promoted the osteogenic capacity of DM-BMSCs via the AMPK/BMP/Smad signalling pathway, and 125 μM was the optimal concentration; however, concentrations over 200 µM, metformin showed an inhibitory effect on DM-BMSCs. Additionally, metformin at the optimal concentration (125 µM) identified in this study could compensate for the negative impacts of T2DM on the osteogenic differentiation of BMSCs. CONCLUSIONS:
Metformin can promote the osteogenesis of BMSCs from T2DM patients and osseointegration in rats, and it might be an effective drug for increasing the success rate of T2DM-associated implants.
|
Authors | Rongxin Sun, Chao Liang, Yujie Sun, Yifan Xu, Wei Geng, Jun Li |
Journal | Oral diseases
(Oral Dis)
Vol. 28
Issue 4
Pg. 1170-1180
(May 2022)
ISSN: 1601-0825 [Electronic] Denmark |
PMID | 33606350
(Publication Type: Journal Article)
|
Copyright | © 2021 Wiley Periodicals LLC. |
Chemical References |
|
Topics |
- Animals
- Cell Differentiation
- Cells, Cultured
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism)
- Humans
- Mesenchymal Stem Cells
- Metformin
(pharmacology)
- Osseointegration
- Osteogenesis
- Rats
- Rats, Wistar
|